|
1
|
de Visser KE and Joyce JA: The evolving
tumor microenvironment: From cancer initiation to metastatic
outgrowth. Cancer Cell. 41:374–403. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dhanasekaran R, Deutzmann A,
Mahauad-Fernandez WD, Hansen AS, Gouw AM and Felsher DW: The MYC
oncogene-the grand orchestrator of cancer growth and immune
evasion. Nat Rev Clin Oncol. 19:23–36. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hill W, Weeden CE and Swanton C: Tumor
promoters and opportunities for molecular cancer prevention. Cancer
Discov. 14:1154–1160. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gilbertson RJ: Mapping cancer origins.
Cell. 145:25–29. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Curtius K, Wright NA and Graham TA: An
evolutionary perspective on field cancerization. Nat Rev Cancer.
18:19–32. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mullard A: Addressing cancer's grand
challenges. Nat Rev Drug Discov. 19:825–826. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Boshuizen J and Peeper DS: Rational cancer
treatment combinations: An urgent clinical need. Mol Cell.
78:1002–1018. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y and Zhang Z: The history and
advances in cancer immunotherapy: Understanding the characteristics
of tumor-infiltrating immune cells and their therapeutic
implications. Cell Mol Immunol. 17:807–821. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Szeto GL and Finley SD: Integrative
approaches to cancer immunotherapy. Trends Cancer. 5:400–410. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hoy SM: Sintilimab: First global approval.
Drugs. 79:341–346. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen S, Li T, Yang W, Wang T, Qin Y, Du Z,
Li Y, Cui P, Hu Y and Liu Z: Comparative efficacy of six programmed
cell death protein-1 inhibitors as first-line treatment for
advanced non-small cell lung cancer: A multicenter retrospective
cohort study. Front Pharmacol. 15:13908722024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang L, Qian Y, Li J, Cui C, Chen L, Qu S
and Lu S: Indirect comparison of sintilimab and other PD-L1
inhibitors for first-line treatment of non-squamous non-small-cell
lung cancer. Future Oncol. 18:1896–1905. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaplon H, Chenoweth A, Crescioli S and
Reichert JM: Antibodies to watch in 2022. MAbs. 14:20142962022.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang L, Lin W, Tan F, Li N, Xue Q, Gao S,
Gao Y and He J: Sintilimab for the treatment of non-small cell lung
cancer. Biomark Res. 10:232022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lou B, Wei H, Yang F, Wang S, Yang B,
Zheng Y, Zhu J and Yan S: preclinical characterization of GLS-010
(Zimberelimab), a novel fully human anti-PD-1 therapeutic
monoclonal antibody for cancer. Front Oncol. 11:7369552021.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mao C, Xiong A, Qian J, Wang W, Liu Y,
Zhang T, Wu Z, Ni H, Lu J, Long S, et al: Dual inhibition of LAG-3
and PD-1 with IBI110 and sintilimab in advanced solid tumors: The
first-in-human phase Ia/Ib study. J Hematol Oncol. 17:1322024.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang L, Mai W, Jiang W and Geng Q:
Sintilimab: A promising anti-tumor PD-1 antibody. Front Oncol.
10:5945582020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu X and Yi Y: Recent updates on
Sintilimab in solid tumor immunotherapy. Biomark Res. 8:692020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao S, Li N, Gao S, Xue Q, Ying J, Wang S,
Tao X, Zhao J, Mao Y, Wang B, et al: Neoadjuvant PD-1 inhibitor
(Sintilimab) in NSCLC. J Thorac Oncol. 15:816–826. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ye Z, Yang W, Xuan B, Li X, He J, Si H and
Ma W: Efficacy and safety evaluation of sintilimab for cancer
treatment: A systematic review and meta-analysis of randomized
controlled trials. Front Pharmacol. 13:8951872022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu J, Li Y, Chen X, Luo C and Zuo X:
Pulmonary fibrosis and cytokine release syndrome after
hyperactivation with sintilimab. J Clin Pharm Ther. 45:1474–1477.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ramos-Casals M, Brahmer JR, Callahan MK,
Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X,
Prat A and Suárez-Almazor ME: Immune-related adverse events of
checkpoint inhibitors. Nat Rev Dis Primers. 6:382020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang Y, Zhu L, Ma X, Hong Y, Su X, Lai W
and Gong Z: A case of sintilimab-induced SJS/TEN:Dermatologic
adverse reactions associated with programmed cell death protein-1
inhibitors. Dermatol Ther. 35:e156632022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang M, Dang P, Liu T, Yang K, Wang Y, Tse
G, Liu H, Liu Y, Chan JSK, Liu C and Li G: Risk factors and
outcomes of pericardial effusion in cancer patients receiving PD-1
inhibitors. Int J Cardiol. 407:1320292024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang
T, Li W and Xia Y: Management of locally advanced non-small cell
lung cancer: State of the art and future directions. Cancer Commun
(Lond). 44:23–46. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mountzios G, Remon J, Hendriks LEL,
García-Campelo R, Rolfo C, Van Schil P, Forde PM, Besse B, Subbiah
V, Reck M, et al: Immune-checkpoint inhibition for resectable
non-small-cell lung cancer-opportunities and challenges. Nat Rev
Clin Oncol. 20:664–677. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Wang Z, Fang J, Yu Q, Han B, Cang
S, Chen G, Mei X, Yang Z, Stefaniak V, et al: Final overall
survival data of sintilimab plus pemetrexed and platinum as
first-line treatment for locally advanced or metastatic nonsquamous
NSCLC in the phase 3 ORIENT-11 study. Lung Cancer. 171:56–60. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang Y, Zhou H and Zhang L: Response to
letter to the editor: Efficacy and safety of sintilimab plus
pemetrexed and platinum as first-line treatment for locally
advanced or metastatic nonsquamous NSCLC: A randomized,
double-blind, phase 3 study (ORIENT-11). J Thorac Oncol.
15:e191–e192. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu SYM, Huang J, Deng JY, Xu CR, Yan HH,
Yang MY, Li YS, Ke EE, Zheng MY, Wang Z, et al: PD-L1 expression
guidance on sintilimab versus pembrolizumab with or without
platinum-doublet chemotherapy in untreated patients with advanced
non-small cell lung cancer (CTONG1901): A phase 2, randomized,
controlled trial. Sci Bull (Beijing). 69:535–543. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dehghani T, Shahrjerdi A, Kahrizi MS,
Soleimani E, Ravandeh S, Merza MS, Rahnama N, Ebrahimzadeh F and
Bakhshesh M: Targeting programmed cell death protein 1 (PD-1) for
treatment of non-small-cell lung carcinoma (NSCLC); the recent
advances. Pathol Res Pract. 246:1544702023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cuesta ÁM, Palao N, Bragado P,
Gutierrez-Uzquiza A, Herrera B, Sánchez A and Porras A: New and old
key players in liver cancer. Int J Mol Sci. 24:171522023.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni
A, Kamel IR, Cloyd JM and Pawlik TM: Management of hepatocellular
carcinoma: A review. JAMA Surg. 158:410–420. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Llovet JM, Pinyol R, Yarchoan M, Singal
AG, Marron TU, Schwartz M, Pikarsky E, Kudo M and Finn RS: Adjuvant
and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat
Rev Clin Oncol. 21:294–311. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li
Q, Lu Y, Chen Y, Guo Y, et al: Sintilimab plus a bevacizumab
biosimilar (IBI305) versus sorafenib in unresectable hepatocellular
carcinoma (ORIENT-32): A randomised, open-label, phase 2–3 study.
Lancet Oncol. 22:977–990. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sidaway P: Adjuvant sintilimab effective
in high-risk HCC. Nat Rev Clin Oncol. 21:1682024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Karimi P, Islami F, Anandasabapathy S,
Freedman ND and Kamangar F: Gastric cancer: Descriptive
epidemiology, risk factors, screening, and prevention. Cancer
Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Smyth EC, Nilsson M, Grabsch HI, van
Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shitara K: Chemotherapy for advanced
gastric cancer: Future perspective in Japan. Gastric Cancer. 20
(Suppl 1):S102–S110. 2017. View Article : Google Scholar
|
|
39
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Taieb J, Moehler M, Boku N, Ajani JA, Ruiz
EY, Ryu MH, Guenther S, Chand V and Bang YJ: Evolution of
checkpoint inhibitors for the treatment of metastatic gastric
cancers: Current status and future perspectives. Cancer Treat Rev.
66:104–113. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mei Y, Shi M and Zhu Z, Yuan H, Yan C, Li
C, Feng T, Yan M, Zhang J and Zhu Z: Addition of sintilimab to
nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy
in stage IIIC gastric cancer. Future Oncol. 18:139–148. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Janjigian YY, Shitara K, Moehler M,
Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T,
Bragagnoli AC, et al: First-line nivolumab plus chemotherapy versus
chemotherapy alone for advanced gastric, gastro-oesophageal
junction, and oesophageal adenocarcinoma (CheckMate 649): A
randomised, open-label, phase 3 trial. Lancet. 398:27–40. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L,
Shu Y, Li J, Zhao J, Pan H, et al: Sintilimab Plus chemotherapy for
unresectable gastric or gastroesophageal junction cancer: The
ORIENT-16 randomized clinical trial. JAMA. 330:2064–2074. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mwachiro M and White R: Management of
esophageal cancer treatment in resource-limited settings. Thorac
Surg Clin. 32:397–404. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang FL and Yu SJ: Esophageal cancer:
Risk factors, genetic association, and treatment. Asian J Surg.
41:210–215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li Q, Liu T and Ding Z: Neoadjuvant
immunotherapy for resectable esophageal cancer: A review. Front
Immunol. 13:10518412022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yokota T, Ando N, Igaki H, Shinoda M, Kato
K, Mizusawa J, Katayama H, Nakamura K, Fukuda H and Kitagawa Y:
Prognostic factors in patients receiving neoadjuvant 5-fluorouracil
plus cisplatin for advanced esophageal cancer (JCOG9907). Oncology.
89:143–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang
L, Wang B, Sun G, Ji Y, Cao G, et al: Sintilimab versus placebo in
combination with chemotherapy as first line treatment for locally
advanced or metastatic oesophageal squamous cell carcinoma
(ORIENT-15): Multicentre, randomised, double blind, phase 3 trial.
BMJ. 377:e0687142022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Benson AB, D'Angelica MI, Abrams T, Abbott
DE, Ahmed A, Anaya DA, Anders R, Are C, Bachini M, Binder D, et al:
NCCN guidelines® insights: Biliary tract cancers,
version 2.2023. J Natl Compr Canc Netw. 21:694–704. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kalyan A, Khosla H and Kim RD:
Immunotherapy in biliary tract cancers: Where are we? Curr Oncol
Rep. 24:1821–1828. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Feng L, Wang Y, Xu H and Yi F: Comparison
of different first-line systemic therapies in advanced biliary
tract cancer based on updated random controlled trials: A
systematic review and network meta-analysis. Biomed Res Int.
2022:17206962022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zeng TM, Yang G, Lou C, Wei W, Tao CJ,
Chen XY, Han Q, Cheng Z, Shang PP, Dong YL, et al: Clinical and
biomarker analyses of sintilimab plus gemcitabine and cisplatin as
first-line treatment for patients with advanced biliary tract
cancer. Nat Commun. 14:13402023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jin S, Zhao R, Zhou C, Zhong Q, Shi J, Su
C, Li Q, Su X, Chi H, Lu X, et al: Feasibility and tolerability of
sintilimab plus anlotinib as the second-line therapy for patients
with advanced biliary tract cancers: An open-label, single-arm,
phase II clinical trial. Int J Cancer. 152:1648–1658. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Klein AP: Pancreatic cancer epidemiology:
Understanding the role of lifestyle and inherited risk factors. Nat
Rev Gastroenterol Hepatol. 18:493–502. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Koikawa K, Kibe S, Suizu F, Sekino N, Kim
N, Manz TD, Pinch BJ, Akshinthala D, Verma A, Gaglia G, et al:
Targeting Pin1 renders pancreatic cancer eradicable by synergizing
with immunochemotherapy. Cell. 184:4753–4771.e27. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
McGrail DJ, Pilié PG, Rashid NU, Voorwerk
L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB and Lim B:
High tumor mutation burden fails to predict immune checkpoint
blockade response across all cancer types. Ann Oncol. 32:661–672.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fu Q, Chen Y, Huang D, Guo C, Zhang X,
Xiao W, Xue X, Zhang Q, Li X, Gao S, et al: Sintilimab plus
modified FOLFIRINOX in metastatic or recurrent pancreatic cancer:
The randomized phase II CISPD3 trial. Ann Surg Oncol. 30:5071–5080.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhou SQ, Wan P, Zhang S, Ren Y, Li HT and
Ke QH: Programmed cell death 1 inhibitor sintilimab plus concurrent
chemoradiotherapy for locally advanced pancreatic adenocarcinoma.
World J Clin Oncol. 15:859–866. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Qiu X, Lu C, Sha H, Zhu Y, Kong W, Tong F,
Wang Q, Meng F, Liu B and Du J: Efficacy and safety of second-line
therapy by S-1 combined with sintilimab and anlotinib in pancreatic
cancer patients with liver metastasis: A single-arm, phase II
clinical trial. Front Immunol. 15:12108592024. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM
and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhang X, Wu T, Cai X, Dong J, Xia C, Zhou
Y, Ding R, Yang R, Tan J, Zhang L, et al: Neoadjuvant immunotherapy
for MSI-H/dMMR locally advanced colorectal cancer: New strategies
and unveiled opportunities. Front Immunol. 13:7959722022.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Diaz LA Jr, Shiu KK, Kim TW, Jensen BV,
Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs
P, et al: Pembrolizumab versus chemotherapy for microsatellite
instability-high or mismatch repair-deficient metastatic colorectal
cancer (KEYNOTE-177): Final analysis of a randomised, open-label,
phase 3 study. Lancet Oncol. 23:659–670. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Xiao WW, Chen G, Gao YH, Lin JZ, Wu XJ,
Luo HL, Lu ZH, Wang QX, Sun R, Cai PQ, et al: Effect of neoadjuvant
chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR
locally advanced rectal cancer: A randomized clinical trial. Cancer
Cell. 42:1570–1581. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Chen G, Jin Y, Guan WL, Zhang RX, Xiao WW,
Cai PQ, Liu M, Lin JZ, Wang FL, Li C, et al: Neoadjuvant PD-1
blockade with sintilimab in mismatch-repair deficient, locally
advanced rectal cancer: An open-label, single-centre phase 2 study.
Lancet Gastroenterol Hepatol. 8:422–431. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Abu-Rustum NR, Yashar CM, Arend R, Barber
E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Crispens MA,
et al: NCCN Guidelines® insights: Cervical cancer,
version 1.2024. J Natl Compr Canc Netw. 21:1224–1233. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Gadducci A and Cosio S: Neoadjuvant
chemotherapy in locally advanced cervical cancer: Review of the
literature and perspectives of clinical research. Anticancer Res.
40:4819–4828. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Monk BJ, Colombo N, Tewari KS, Dubot C,
Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş
M, et al: First-line pembrolizumab + chemotherapy versus placebo +
chemotherapy for persistent, recurrent, or metastatic cervical
cancer: Final overall survival results of KEYNOTE-826. J Clin
Oncol. 41:5505–5511. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Wang Y, Zhao J, Liang H, Liu J, Huang S,
Zou G, Huang X and Lan C: Efficacy and safety of sintilimab plus
albumin-bound-paclitaxel in recurrent or metastatic cervical
cancer: A multicenter, open-label, single-arm, phase II trial.
EClinicalMedicine. 65:1022742023. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Xu Q, Wang J, Sun Y, Lin Y, Liu J, Zhuo Y,
Huang Z, Huang S, Chen Y, Chen L, et al: Efficacy and safety of
sintilimab plus anlotinib for PD-L1-positive recurrent or
metastatic cervical cancer: A multicenter, single-arm, prospective
phase II trial. J Clin Oncol. 40:1795–1805. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Cuthbertson DJ, Shankland R and
Srirajaskanthan R: Diagnosis and management of neuroendocrine
tumours. Clin Med (Lond). 23:119–124. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Jia R, Li Y, Xu N, Jiang HP, Zhao CH, Liu
RR, Shi Y, Zhang YY, Wang SY, Zhou H and Xu JM: Sintilimab in
patients with previously treated metastatic neuroendocrine
neoplasms. Oncologist. 27:e625–e632. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Liu X, Zhang Y, Yang KY, Zhang N, Jin F,
Zou GR, Zhu XD, Xie FY, Liang XY, Li WF, et al:
Induction-concurrent chemoradiotherapy with or without sintilimab
in patients with locoregionally advanced nasopharyngeal carcinoma
in China (CONTINUUM): A multicentre, open-label, parallel-group,
randomised, controlled, phase 3 trial. Lancet. 403:2720–2731. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Tian Z, Dong S, Yang Y, Gao S, Yang Y,
Yang J, Zhang P, Wang X and Yao W: Nanoparticle albumin-bound
paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for
soft tissue sarcoma: A retrospective study. BMC Cancer. 22:562022.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Lu X, Gu W, Shi G and Ye D: Pazopanib
together with 6–8 cycles of sintilimab followed by single use of
pazopanib in the second-line treatment of advanced renal cell
carcinoma. Transl Androl Urol. 10:2078–2083. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Li X, Fang Q, Du W, Zhang X, Dai L and
Qiao Y: Induction chemotherapy combined with immunotherapy in
locally advanced head and neck squamous cell carcinoma. BMC Cancer.
21:6222021. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Li R, Liu X, Song C, Zhang W, Liu J, Jiao
X, Yu Y, Zeng S, Chi J, Zhao Y, et al: Sintilimab combined with
bevacizumab in relapsed/persistent ovarian clear cell carcinoma
(INOVA): An investigator-initiated, multicentre clinical trial-a
study protocol of clinical trial. BMJ Open. 12:e0581322022.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wei W, Ban X, Yang F, Li J, Cheng X, Zhang
R, Huang X, Huang Y, Li Q, Qiu Y, et al: Phase II trial of
efficacy, safety and biomarker analysis of sintilimab plus
anlotinib for patients with recurrent or advanced endometrial
cancer. J Immunother Cancer. 10:e0043382022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yao G, Huang J, Zhang Q, Hu D, Yuan F and
Han G: Excellent response of refractory triple-negative breast
cancer to sintilimab plus chemotherapy: A case report.
Immunotherapy. 15:221–228. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Molife C, Brnabic A, Stefaniak VJ, Belger
MA, Gruver K, Chen JV, Souri S and Blumenschein GR Jr: Sintilimab
plus chemotherapy for first-line treatment of advanced or
metastatic nonsquamous non-small-cell lung cancer: Network
meta-analysis. Immunotherapy. 15:293–309. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Li F, Chen Y, Xiao D, Jiang S and Yang Y:
Cost-Effectiveness analysis of sintilimab plus chemotherapy in
advanced non-squamous non-small cell lung cancer: A societal
perspective. Adv Ther. 41:1436–1449. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
He J, Huang Z, Han L, Gong Y and Xie C:
Mechanisms and management of 3rd-generation EGFR-TKI resistance in
advanced non-small cell lung cancer (Review). Int J Oncol.
59:902021. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Sangro B, Sarobe P, Hervás-Stubbs S and
Melero I: Advances in immunotherapy for hepatocellular carcinoma.
Nat Rev Gastroenterol Hepatol. 18:525–543. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Cheng J, Li Y, Wang X, Dong Z, Chen Y,
Zhang R, Huang J, Jin X, Yao J, Ge A, et al: Response
stratification in the first-line combined immunotherapy of
hepatocellular carcinoma at genomic, transcriptional and immune
repertoire levels. J Hepatocell Carcinoma. 8:1281–1295. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wang S, Yuan P, Mao B, Li N, Ying J, Tao
X, Tang W, Zhang L, Geng X, Zhang F, et al: Genomic features and
tumor immune microenvironment alteration in NSCLC treated with
neoadjuvant PD-1 blockade. NPJ Precis Oncol. 6:22022. View Article : Google Scholar : PubMed/NCBI
|
